Related Experiment Video
Updated: Feb 27, 2026
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.3K
Warfarin Pharmacogenomics in Diverse Populations
Justin B Kaye1, Lauren E Schultz2, Heidi E Steiner1
1Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy, Tucson, Arizona.
Pharmacotherapy
|July 4, 2017
Summary
Genotype-guided warfarin dosing needs to account for diverse populations. Current algorithms, mostly tested in European ancestry groups, may not benefit African Americans and Latinos due to genetic variations.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Genotype-guided warfarin dosing aims to optimize medication and reduce adverse events.
- Diverse populations, including African Americans and Latinos, exhibit greater warfarin dose variability and risk of adverse events compared to individuals of European ancestry.
Purpose of the Study:
- To highlight the limitations of current genotype-guided warfarin dosing algorithms in diverse populations.
- To emphasize the need for race/ethnicity-specific or admixture-based algorithms for improved warfarin dosing in all patient groups.
Main Methods:
- Review of existing literature on genotype-guided warfarin dosing.
- Analysis of genetic variant frequencies across different race/ethnic groups.
- Evaluation of algorithm performance in diverse populations.
Main Results:
- The majority of genotype-guided warfarin dosing research, including clinical trials, is based on populations of European ancestry.
- Current algorithms often overlook genetic variants crucial for diverse populations, limiting their benefit.
- Race/ethnicity-specific or admixture-based algorithms may offer superior warfarin dose optimization in certain groups.
Conclusions:
- Successful clinical implementation of warfarin pharmacogenomics requires careful consideration of race/ethnicity.
- Development of improved, inclusive genotype-guided warfarin dosing algorithms is essential for equitable patient care.
- This highlights the broader need to incorporate race/ethnicity in pharmacogenomic research and clinical recommendations.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
01:27Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
01:27Principles of Pharmacogenetics: Types of Genetic Variants
59
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
59
01:29Pharmacogenetics and Pharmacogenomics: Overview
74
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
45
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
45
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K